Astrazeneca (AZN) and Daiichi Sankyo are in advanced talks with England's drug pricing regulator to make the breast cancer medicine Enhertu available to certain patients, Bloomberg reported Wednesday, citing people familiar with the negotiations.

According to the report, Enhertu can extend the lives of some breast cancer patients by around six months. Bloomberg said about 1,000 women in England and Wales could benefit from the treatment, but currently do not have access, as the National Institute for Health and Care Excellence sees the drug as too expensive.

Bloomberg reported that if an agreement is reached, the National Health Service England is expected to secure a lower price than in many other European countries where the drug is already widely available.

In an emailed statement to MT Newswires, an AstraZeneca spokesperson said discussions "are ongoing with NHS England and NICE to identify a solution to support access to Enhertu for HER2-low metastatic breast cancer patients in England, Wales and Northern Ireland."

Daiichi Sankyo did not immediately respond to MT Newswires' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)